Lenalidomide, bortezomib, pegylated liposomal doxorubicin, and dexamethasone in newly diagnosed multiple myeloma: a phase 1/2 Multiple Myeloma Research Consortium trial

Pre-clinical evaluation of bortezomib, doxorubicin, dexamethasone, and lenalidomide in multiple myeloma (MM)

(2017) M. Hari et al.   JOURNAL OF CLINICAL ONCOLOGY

Comparison of reduced-dose bortezomib plus thalidomide plus dexamethasone (vTD) to bortezomib plus dexamethasone (VD) as induction treatment prior to ASCT in de novo multiple myeloma (MM): Results of IFM2007-02 study.

(2017) P. Moreau et al.   JOURNAL OF CLINICAL ONCOLOGY

Bortezomib, melphalan, prednisone, and thalidomide (VMPT) followed by maintenance with bortezomib and thalidomide (VT) for initial treatment of elderly multiple myeloma patients.

(2017) M. Boccadoro et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase I study of combined vorinostat (V), lenalidomide (L), and dexamethasone (D) in patients (pts) with relapsed or refractory multiple myeloma (MM).

(2017) P. G. Richardson et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase Ib study of oral panobinostat (LBH589) plus lenalidomide (LEN) plus dexamethasone (DEX) in patients (Pts) with relapsed (Rel) or Rel and refractory (Ref) multiple myeloma (MM).

(2017) M. Mateos et al.   JOURNAL OF CLINICAL ONCOLOGY

Elotuzumab in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myeloma: A phase I/II study.

(2017) S. Lonial et al.   JOURNAL OF CLINICAL ONCOLOGY

Another Lnk to STAT activation

(2010) K. D. Bunting   BLOOD

Superior outcomes associated with complete response in newly diagnosed multiple myeloma patients treated with nonintensive therapy: analysis of the phase 3 VISTA study of bortezomib plus melphalan-prednisone versus melphalan-prednisone

(2010) J.-L. Harousseau et al.   BLOOD

Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma

(2010) P. G. Richardson et al.   BLOOD

Induction Treatment With Cyclophosphamide, Thalidomide, and Dexamethasone in Newly Diagnosed Multiple Myeloma: A Phase II Study

(2010) Deok-Hwan Yang et al.   Clinical Lymphoma Myeloma & Leukemia

Rapid control of previously untreated multiple myeloma with bortezomib–lenalidomide–dexamethasone (BLD)

(2010) M. Wang et al.   Hematology

Bortezomib-Melphalan-Prednisone-Thalidomide Followed by Maintenance With Bortezomib-Thalidomide Compared With Bortezomib-Melphalan-Prednisone for Initial Treatment of Multiple Myeloma: A Randomized Controlled Trial

(2010) Antonio Palumbo et al.   JOURNAL OF CLINICAL ONCOLOGY

Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study

(2010) Michele Cavo et al.   LANCET

Bortezomib, dexamethasone, cyclophosphamide and lenalidomide combination for newly diagnosed multiple myeloma: phase 1 results from the multicenter EVOLUTION study

(2010) S K Kumar et al.   LEUKEMIA

Bortezomib, thalidomide, dexamethasone induction therapy followed by melphalan, prednisolone, thalidomide consolidation therapy as a first line of treatment for patients with multiple myeloma who are non-transplant candidates: results of the Korean Multiple Myeloma Working Party (KMMWP)

(2009) Hyeon-Seok Eom et al.   ANNALS OF HEMATOLOGY

Phase 2 study of two sequential three-drug combinations containing bortezomib, cyclophosphamide and dexamethasone, followed by bortezomib, thalidomide and dexamethasone as frontline therapy for multiple myeloma

(2009) William I. Bensinger et al.   BRITISH JOURNAL OF HAEMATOLOGY

Achievement of at Least Very Good Partial Response Is a Simple and Robust Prognostic Factor in Patients With Multiple Myeloma Treated With High-Dose Therapy: Long-Term Analysis of the IFM 99-02 and 99-04 Trials

(2009) Jean-Luc Harousseau et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II Trial of Combination Therapy With Bortezomib, Pegylated Liposomal Doxorubicin, and Dexamethasone in Patients With Newly Diagnosed Myeloma

(2009) Andrzej J. Jakubowiak et al.   JOURNAL OF CLINICAL ONCOLOGY

Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: high response rates in a phase II clinical trial

(2009) C B Reeder et al.   LEUKEMIA

The relationship between quality of response and clinical benefit for patients treated on the bortezomib arm of the international, randomized, phase 3 APEX trial in relapsed multiple myeloma

(2008) Ruben Niesvizky et al.   BRITISH JOURNAL OF HAEMATOLOGY

Bortezomib, doxorubicin and dexamethasone (PAD) front-line treatment of multiple myeloma: updated results after long-term follow-up

(2008) Rakesh Popat et al.   BRITISH JOURNAL OF HAEMATOLOGY

Bortezomib in the front-line treatment of multiple myeloma

(2008) Paul G Richardson et al.   Expert Review of Anticancer Therapy